Pre-treatment HIV drug resistance testing cost-effectiveness

EClinicalMedicine. 2020 May 22:22:100381. doi: 10.1016/j.eclinm.2020.100381. eCollection 2020 May.

Authors

David Amc van de Vijver¹, Brooke E Nichols^{2

3}

Affiliations

¹ Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
² Department of Global Health, Boston University School of Public Health, Boston, United States.
³ Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

No abstract available